<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0241552.ref036">
 <label>36</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Scott</surname>
   <given-names>RA</given-names>
  </name>, 
  <name>
   <surname>Freitag</surname>
   <given-names>DF</given-names>
  </name>, 
  <name>
   <surname>Li</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Chu</surname>
   <given-names>AY</given-names>
  </name>, 
  <name>
   <surname>Surendran</surname>
   <given-names>P</given-names>
  </name>, 
  <name>
   <surname>Young</surname>
   <given-names>R</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease</article-title>. 
  <source>Sci Transl Med</source>. 
  <year>2016</year>;
  <volume>8</volume>(
  <issue>341</issue>):
  <fpage>341ra76</fpage>
  <pub-id pub-id-type="doi">10.1126/scitranslmed.aad3744</pub-id>
  <?supplied-pmid 27252175?>
  <pub-id pub-id-type="pmid">27252175</pub-id>
 </mixed-citation>
</ref>
